| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Hypertension. 2007;50:432.)
© 2007 American Heart Association, Inc.
Original Articles |
and ß, Attenuate Cardiovascular Remodeling in Aldosterone SaltTreated RatsFrom the Medizinische Klinik I (P-A.A.-L., K.H., C.D., V.J., T.P.), University of Würzburg, Würzburg, Germany; Integrated Functional Genomics (A.M.M., S.K.), IZKF University of Münster, Münster, Germany; Division of Cardiology (L.N.), University of Manchester, Manchester, United Kingdom; and Schering AG (C.H-H., K.H.F.), Berlin, Germany.
Experimental and population-based studies indicate that female gender and estrogens protect the cardiovascular system against aldosterone-induced injury. Understanding the function of estrogens in heart disease requires more precise information on the role of both estrogen receptor (ER) subtypes, ER
and ERß. Therefore, we determined whether selective activation of ER
or of ERß would confer redundant, specific, or opposing effects on cardiovascular remodeling in aldosterone salttreated rats. The ER
agonist 16
-LE2, the ERß agonist 8ß-VE2, and the nonselective estrogen receptor agonist 17ß-estradiol lowered elevated blood pressure, cardiac mass, and cardiac myocyte cross-sectional areas, as well as increased perivascular collagen accumulation and vascular osteopontin expression in ovariectomized rats receiving chronic aldosterone infusion plus a high-salt diet for 8 weeks. Uterus atrophy was prevented by 16
-LE2 and 17ß-estradiol but not by 8ß-VE2. Cardiac proteome analyses by 2D gel electrophoresis, mass spectrometry, and peptide sequencing identified specific subsets of proteins involved in cardiac contractility, energy metabolism, cellular stress response and extracellular matrix formation that were regulated in opposite directions by aldosterone salt treatment and by different estrogen receptor agonists. We conclude that activation of either ER
or ERß protects the cardiovascular system against the detrimental effects of aldosterone salt treatment and confers redundant, as well as specific, effects on cardiac protein expression. Nonfeminizing ERß agonists such as 8ß-VE2 have a therapeutic potential in the treatment of hypertensive heart disease.
Key Words: aldosterone estrogen proteomics hypertrophy inflammation
Related Article:
Hypertension 2007 50: 297-298.
This article has been cited by other articles:
![]() |
B. Xue, D. Badaue-Passos Jr, F. Guo, C. E. Gomez-Sanchez, M. Hay, and A. K. Johnson Sex differences and central protective effect of 17{beta}-estradiol in the development of aldosterone/NaCl-induced hypertension Am J Physiol Heart Circ Physiol, May 1, 2009; 296(5): H1577 - H1585. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Jazbutyte, P. A. Arias-Loza, K. Hu, J. Widder, V. Govindaraj, C. von Poser-Klein, J. Bauersachs, K.-H. Fritzemeier, C. Hegele-Hartung, L. Neyses, et al. Ligand-dependent activation of ER{beta} lowers blood pressure and attenuates cardiac hypertrophy in ovariectomized spontaneously hypertensive rats Cardiovasc Res, March 1, 2008; 77(4): 774 - 781. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. C. Barbato Estrogen Receptor Activation--Good, Aldosterone Receptor Blockade--Beneficial, Communication Between Receptors...Priceless Hypertension, August 1, 2007; 50(2): 297 - 298. [Full Text] [PDF] |
||||
|
Hypertension Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2007 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |